SCHEDULE 14A INFORMATION
    Proxy Statement Pursuant to Section 14(a) of the
                        Securities Exchange Act of 1934
                                (Amendment No. )

Filed by the Registrant  [X ]

Filed by a Party other than the Registrant  [  ]

Check the appropriate box:

[  ]  Preliminary Proxy Statement

[  ]  Confidential, for Use of the Commission Only (as permitted by Rule
      14a-6(e)(2))

[  ]  Definitive Proxy Statement

[  ]  Definitive Additional Materials

[X ]  Soliciting Material Pursuant to Sections 240.14a-11(c) or Section
      240.14a-12

                           NORTHFIELD LABORATORIES, INC.
- --------------------------------------------------------------------------------
                (Name of Registrant as Specified In Its Charter)


                           MANAGEMENT INSIGHTS, INC.
- --------------------------------------------------------------------------------
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

[ X]  No fee required

[  ]  Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11

   1) Title of each class of securities to which transaction applies:

   2) Aggregate number of securities to which transaction applies:

   3)  Per unit price or other underlying value of transaction computed pursuant
       to Exchange Act Rule 0-11 (set forth the amount on which the filing fee
       is calculated and state how it was determined):

   4) Proposed maximum aggregate value of transaction:

   5) Total fee paid:

[  ]  Fee paid previously with preliminary materials

[  ]  Check box if any part of the fee is offset as provided by Exchange Act
      Rule 0-11(a)(2) and identify the filing for which the offsetting fee was
      paid previously. Identify the previous filing by registration statement
      number, or the Form or Schedule and the date of its filing.

   1) Amount Previously Paid:

   2) Form, Schedule or Registration Statement No.:

   3) Filing Party:

   4) Date Filed:



FOR IMMEDIATE RELEASE

Contact:
Michael Eden
Management Insights, Inc.
14755 Preston Road   Suite 525
Dallas, TX 75240
(972) 755-2064
meden@managementinsights.com
- ----------------------------

Management Insights, Inc.  Releases Letter to Shareholders of Northfield Labs

Dallas/June 22, 2000/PRNewswire/ -- -- C. Robert Coates and Management Insights,
Inc.  (MII) today  announced they have retained  Beacon Hill  Partners,  Inc. as
strategic  advisor  regarding  opportunities to improve the shareholder value of
Northfield Labs (NASDAQ:  NFLD).  Mr. Coates and MII are significant  Northfield
Labs shareholders.

"We  believe  Northfield's  product,  PolyHeme,  is the  best  blood  substitute
candidate  under  development  and is a testament to the quality of Northfield's
research  staff," said Mr. Coates.  "However,  successful  public companies must
also execute well in such disciplines as investor  relations,  public relations,
and marketing.  Northfield's  management has consistently refused to communicate
details of the  company's  successes and status to  shareholders,  the financial
community,  the  medical  community,  and the press.  This has  resulted  in the
company  being  greatly  undervalued  relative  to such  competitors  as Biopure
Corporation and Alliance Pharmaceutical."

In addition,  C. Robert  Coates and MII  announced  that they have  released the
following letter for mailing to Northfield Labs' shareholders.

                                       ***
                              AN IMPORTANT MESSAGE
                 FOR FELLOW SHAREHOLDERS OF NORTHFIELD LABS INC.
               FROM C. ROBERT COATES AND MANAGEMENT INSIGHTS, INC.

JUNE 19, 2000

Dear Fellow Northfield Shareholder:

We  own  640,800  shares  of  Northfield  Labs,  Inc.   (approximately  4.5%  of
Northfield's  outstanding  shares) as of June 19, 2000.  As one of  Northfield's
largest  shareholders,  we have concerns  about our  Management's  commitment to
maximizing shareholder value and about our declining stock price.

Our current Management has effectively adopted a "Wall of Silence" policy toward
communicating  with  shareholders,  the medical  community,  the press, and Wall
Street.  No press  releases  describing the status of  Northfield's  products or
clinical trials have been released since May 4, 1999.  Northfield's SEC Form 10Q
and 10K reports all contain  essentially  the same  vaguely  worded  boilerplate
descriptions of the Company's  status.  Information from the Company's  Investor
Relations Department is bereft of detail.



We, the  shareholders,  have paid the price for this policy. We have spoken with
several Wall Street analysts and institutions, and they have confirmed that this
lack of  communication  has raised the perceived level of risk of the Company to
investors. Over the past twelve months, the share prices of Northfield's primary
competitors,   Biopure  Corporation  and  Alliance   Pharmaceutical  have  risen
significantly.  Northfield shares,  however, are trading at essentially the same
price as a year ago.



                                PERFORMANCE COMPARISONS - BLOOD SUBSTITUTE COMPANIES



- ----------------------------------------------------------------------------------------------------------
                         June 18, 1999  June 19, 2000    % Change    Market Capitalization   Institutional
                                                                                             Ownership
- ----------------------------------------------------------------------------------------------------------

- ----------------------------------------------------------------------------------------------------------
                                                                                    
Alliance Pharmaceutical  $   2 7/16     $  10 3/4       341%         $  507.2M                     26%
- ----------------------------------------------------------------------------------------------------------
Biopure Corporation      $ 10 1/4 *     $  18 3/8         79%        $  458.1M                     29%
- ----------------------------------------------------------------------------------------------------------
Northfield Labs          $ 12           $  12 7/16         4%        $  177.1M                     10%
- ----------------------------------------------------------------------------------------------------------

                           * As of close of trading on IPO date 30 July 1999


According to published reports, our Product, PolyHeme, is a leading candidate in
the  search  for a safe and  effective  blood  substitute.  It is the only blood
substitute  product under development that has been successfully used to rapidly
replace essentially ALL of a human being's blood. In fact, up to twice the total
adult blood volume has,  effectively,  been given  without any  appreciable  ill
effects.  This achievement is unprecedented,  and all competing substitutes have
significant  side effects that have not been  encountered  with  PolyHeme.  This
remarkable  product has the potential to save  countless  lives  throughout  the
world in severe trauma and rapid hemorrhage situations, not to mention a variety
of other  potential  applications.  The benefits of a red blood cell  substitute
with a long  shelf  life,  that is free of the risk of disease  transmission  or
transfusion  reaction and can be given without  preceding lab tests, even in the
field,  cannot be  overstated.  Despite this, the Company is valued at much less
than half that of Biopure Corporation or Alliance Pharmaceutical.

I believe this under-performance is attributable to the following:

     1)   Lack  of  communication   with  Wall  Street  industry   analysts  and
          institutions
     2)   Lack of communication with the shareholders and the press
     3)   Lack of publication in medical journals and other scientific media
     4)   Lack of announced  progress in  contracting  for a reliable  source of
          outdated blood for use in the manufacturing process
     5)   Lack  of   announced   progress   in   recruiting   distribution   and
          manufacturing partners
     6)   Lack of commitment to marketing and PR awareness campaigns

I WOULD LIKE TO SEE NORTHFIELD  LABS  MANAGEMENT  IMPROVE  SHAREHOLDER  VALUE BY
ADDRESSING THESE DEFICIENCIES IMMEDIATELY.  I AM NOT SUGGESTING THAT THE COMPANY
SHOULD ENGAGE IN A POLICY OF HYPING THE STOCK; I DO, HOWEVER,  EXPECT MANAGEMENT
AND THE BOARD TO OPENLY  AND  REGULARLY  COMMUNICATE  WITH US TO  FULFILL  THEIR
FIDUCIARY DUTY.

REMEMBER:  THIS IS OUR  COMPANY!  WE HAVE THE  RIGHT TO ASK THAT OUR  LEADERSHIP
ACTIVELY SEEK TO MAXIMIZE SHAREHOLDER VALUE!



I  will  be  actively  encouraging   Northfield   Management  to  adopt  a  more
shareholder-friendly  approach and urge you to do the same.  I would  appreciate
hearing your concerns as well.

Best regards,

C. Robert Coates
Chief Executive Officer
Management Insights, Inc.

                                       ***
About Management Insights, Inc.
- -------------------------------
Management Insights, Inc. (MII) is a diversified management consulting,  venture
capital,  and  investment  firm.  Its customers  include a number of Fortune 500
companies.  Among its  public  investments  are large  equity  stakes in Inprise
Corporation (NASDAQ:  INPR), Evolving Systems (NASDAQ: EVOL) and Northfield Labs
(NASDAQ: NFLD). Through its ProxyCapital Partners,  Inc. subsidiary,  MII serves
as fund manager for ProxyCapital LP, a value-oriented hedge fund.







                            MANAGEMENT INSIGHTS INC.
                          14755 PRESTON ROAD, SUITE 525
                                DALLAS, TX 75240
                                 (972) 755-2100
                        NORTHFIELD@MANAGEMENTINSIGHTS.COM


     We would like to hear from you. We would  appreciate it if you would take a
few minutes to fill out the information requested below.

     Thank you for your time and cooperation.
- --------------------------------------------------------------------------------

SHAREHOLDER INFORMATION

                               NAME: ___________________________________________

FIRM:                _______________________________________________

ADDRESS:           ________________________________________________

CITY:                  __________________________STATE: ____ZIP: ________

PHONE:               ____________________________FAX:  ______________

I HOLD MY NORTHFIELD LABS INC. SHARES THROUGH:

- ------------------------------         --------------------------
(NAME OR BROKERAGE FIRM OR BANK)              (NUMBER OF SHARES OWNED)


                                   STOCK BROKER OR FINANCIAL ADVISOR INFORMATION

                               NAME: ___________________________________________

FIRM:                _______________________________________________

ADDRESS:           _______________________________________________

CITY:                  __________________________STATE: ____ZIP: ________

PHONE:               ____________________________FAX:  ______________




COMMENTS:       ________________________________________________________________

- -----------------------------------------------------------------------------

- -----------------------------------------------------------------------------

- -----------------------------------------------------------------------------

- -----------------------------------------------------------------------------



- --------------------------------------------------------------------------------
    PLEASE RETURN THIS FORM TO OUR ATTENTION AT THE ADDRESS INDICATED ABOVE.
- --------------------------------------------------------------------------------
 IF YOU PREFER, YOU MAY FAX IT TO OUR OFFICES AT (972) 755-2080 ATTN: NORTHFIELD